Sales Nexus CRM

Helus Pharma Reports Fiscal Q2 2027 Results, Advances Phase 3 Pipeline for Depression and Anxiety

By FisherVista•
Helus Pharma's fiscal Q2 2027 results show a widened net loss but highlight progress in its Phase 3 program for major depressive disorder and plans for a Phase 2 anxiety study, underscoring the costly but potentially impactful development of novel serotonergic agonists.
Helus Pharma Reports Fiscal Q2 2027 Results, Advances Phase 3 Pipeline for Depression and Anxiety

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., reported financial results and business updates for its fiscal second quarter ended Sept. 30, 2026, emphasizing continued development of its novel serotonergic agonist (NSA) pipeline. The company ended the quarter with $171.1 million in cash and reported a net loss of $103.1 million, compared with $33.7 million in the prior-year period. Operating expenses excluding share-based compensation increased to $39.6 million from $28.5 million, primarily reflecting continued advancement of its Phase 3 clinical program. Cash used in operating activities totaled $35.3 million, compared with $34.5 million a year earlier.

During the quarter, Helus Pharma completed enrollment in APPROACH, its pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder (MDD), while enrollment continued in the EMBRACE and EXTEND studies. The company also outlined plans to initiate a Phase 2 monotherapy study of HLP004 for generalized anxiety disorder in the first quarter of 2027 and expects to select a development candidate for its HLP005 program in the second half of 2027. To view the full press release, visit https://ibn.fm/yu74F.

The widening net loss reflects the heavy investment required to advance a late-stage clinical pipeline. Helus Pharma is developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity—intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD, a status that may expedite review and underscores the therapy's potential. With class-leading data, the company aims to improve the treatment landscape through NSAs that provide durable improvements in mental health.

The completion of enrollment in the APPROACH study is a critical milestone, as it moves Helus Pharma closer to a potential regulatory submission for HLP003. If successful, the therapy could offer a new option for patients with MDD who do not respond adequately to existing treatments. The planned Phase 2 study of HLP004 in generalized anxiety disorder and the HLP005 candidate selection next year further broaden the pipeline, potentially addressing multiple psychiatric conditions with significant unmet need.

Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.

The announcement is disseminated by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For investors, the cash position and pipeline progress are key metrics to watch as Helus Pharma advances its late-stage programs.

FisherVista

FisherVista

@fishervista